BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20. [PMID: 9489902 DOI: 10.1080/00365529850166149] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Aanen MC, Weusten BL, Numans ME, de Wit NJ, Baron A, Smout AJ. Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther. 2006;24:1377-1384. [PMID: 17059519 DOI: 10.1111/j.1365-2036.2006.03121.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
2 Varannes SBD, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: Results of a study in a primary care setting. World J Gastroenterol 2006; 12(16): 2569-2573 [PMID: 16688803 DOI: 10.3748/wjg.v12.i16.2569] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
3 van Herwaarden MA, Smout AJ. Diagnosis of reflux disease. Best Practice & Research Clinical Gastroenterology 2000;14:759-74. [DOI: 10.1053/bega.2000.0123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
4 Johnsson F, Hatlebakk JG, Klintenberg A, Román J, Toth E, Stubberöd A, Falk A, Edin R. One-week Esomeprazole Treatment: an Effective Confirmatory Test in Patients with Suspected Gastroesophageal Reflux Disease. Scandinavian Journal of Gastroenterology 2017;38:354-9. [DOI: 10.1080/0036552031002139] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
5 van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;:CD002095. [PMID: 16855986 DOI: 10.1002/14651858.CD002095.pub3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
6 Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80. [PMID: 10403727 DOI: 10.1136/gut.45.2.172] [Cited by in Crossref: 1350] [Cited by in F6Publishing: 1188] [Article Influence: 61.4] [Reference Citation Analysis]
7 Adachi K, Hashimoto T, Hamamoto N, Hirakawa K, Niigaki M, Miyake T, Taniura H, Ono M, Kaji T, Suetsugu H. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J Gastroenterol Hepatol. 2003;18:1392-1398. [PMID: 14675268 DOI: 10.1046/j.1440-1746.2003.03190.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
8 Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003;18:875-882. [PMID: 14616151 DOI: 10.1046/j.1365-2036.2003.01771.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
9 Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology. 2002;122:1270-1285. [PMID: 11984514 DOI: 10.1053/gast.2002.33019] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 4.6] [Reference Citation Analysis]
10 Asakura Y, Imai Y, Ota S, Fujiwara K, Miyamae T. Usefulness of gastroesophageal reflux scintigraphy using the knee-chest position for the diagnosis of gastroesophageal reflux disease. Ann Nucl Med 2005;19:291-6. [DOI: 10.1007/bf02984621] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 Ding ZL, Wang ZF, Sun XH, Ke MY. [Therapeutic mechanism of diaphragm training at different periods in patients with gastroesophageal reflux disease]. Zhonghua Yixue Zazhi. 2013;93:3215-3219. [PMID: 24405544 DOI: 10.1111/j.1365-2036.2004.02241.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
12 Dent J, Armstrong D, Delaney B, Moayyedi P, Talley NJ, Vakil N. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut. 2004;53 Suppl 4:iv1-i24. [PMID: 15082609 DOI: 10.1136/gut.2003.034272] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 3.1] [Reference Citation Analysis]
13 Fass, Ofman, Sampliner, Camargo, Wendel, Fennerty. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis: THE OMEPRAZOLE TEST VS. pH TESTING IN DIAGNOSING GERD. Alimentary Pharmacology & Therapeutics 2000;14:389-96. [DOI: 10.1046/j.1365-2036.2000.00733.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 3.7] [Reference Citation Analysis]
14 Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, Venables T, Green J, Bigard MA, Mössner J. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20:413-421. [PMID: 15298635 DOI: 10.1111/j.1365-2036.2004.02085.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
15 Zheng RN. Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. World J Gastroenterol 2009; 15(8): 990-995 [PMID: 19248200 DOI: 10.3748/wjg.15.990] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kuo P, Holloway RH. A pragmatic symptom-based approach. Best Practice & Research Clinical Gastroenterology 2010;24:765-73. [DOI: 10.1016/j.bpg.2010.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
17 Bytzer P, Jones R, Vakil N, Junghard O, Lind T, Wernersson B, Dent J. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:1360-1366. [PMID: 22813439 DOI: 10.1016/j.cgh.2012.06.030] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
18 Gasiorowska A, Fass R. The proton pump inhibitor (PPI) test in GERD: does it still have a role? J Clin Gastroenterol 2008;42:867-74. [PMID: 18645525 DOI: 10.1097/MCG.0b013e31816c47ed] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
19 Navarro-rodriguez T, Fass R. Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions—A debate: Pro. Curr Treat Options Gastro 2007;10:294-304. [DOI: 10.1007/s11938-007-0072-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
20 Xia HH, Lai KC, Lam SK, Hu WH, Wong NY, Hui WM, Lau CP, Chen WH, Chan CK, Wong WM, Wong BC. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003;17:369-77. [PMID: 12562449 DOI: 10.1046/j.1365-2036.2003.01436.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
21 Marzo M, Alonso P, Bonfill X, Fernández M, Fernández J, Martínez G, Mearín F, Mascort J, Piqué J, Ponce J, Sáez M. Guía de práctica clínica sobre el manejo del paciente con enfermedad por reflujo gastroesofágico (ERGE). Gastroenterología y Hepatología 2002;25:85-110. [DOI: 10.1016/s0210-5705(02)70245-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
22 Tipnis NA, Tipnis SM. Controversies in the Treatment of Gastroesophageal Reflux Disease in Preterm Infants. Clinics in Perinatology 2009;36:153-64. [DOI: 10.1016/j.clp.2008.09.011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
23 Kinoshita Y, Kobayashi T, Kato M, Asahina K, Haruma K, Shimatani T, Inoue S, Kabemura T, Kurosawa S, Kuwayama H, Ashida K, Hirayama M, Kiyama S, Yamamoto M, Suzuki J, Suzuki H, Matsumoto K, Aoshima M. The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol 2006;41:554-61. [PMID: 16868803 DOI: 10.1007/s00535-006-1804-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
24 Johnsson F, Hatlebakk JG, Klintenberg A, Román J. Symptom-relieving Effect of Esomeprazole 40 mg Daily in Patients with Heartburn. Scandinavian Journal of Gastroenterology 2017;38:347-53. [DOI: 10.1080/00365520310002157] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
25 Yoshikawa I, Yamasaki M, Yamasaki T, Kume K, Otsuki M. Lugol chromoendoscopy as a diagnostic tool in so-called endoscopy-negative GERD. Gastrointestinal Endoscopy 2005;62:698-703. [DOI: 10.1016/j.gie.2005.06.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
26 Budzyński J, Kłopocka M, Pulkowski G, Suppan K, Fabisiak J, Majer M, Swiatkowski M. The effect of double dose of omeprazole on the course of angina pectoris and treadmill stress test in patients with coronary artery disease--a randomised, double-blind, placebo controlled, crossover trial. Int J Cardiol 2008;127:233-9. [PMID: 17689732 DOI: 10.1016/j.ijcard.2007.04.079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
27 Lundell L, Dent J. Gastro-oesophageal reflux disease. In: Olbe L, editor. Proton Pump Inhibitors. Basel: Birkhäuser; 1999. pp. 223-35. [DOI: 10.1007/978-3-0348-8795-3_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
28 Sgouros SN, Mantides A. Refractory Heartburn to Proton Pump Inhibitors: Epidemiology, Etiology and Management. Digestion 2006;73:218-27. [DOI: 10.1159/000094789] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
29 Galmiche JP, des Varannes SB. Endoscopy-negative reflux disease. Curr Gastroenterol Rep 2001;3:206-14. [DOI: 10.1007/s11894-001-0023-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
30 Voutilainen M, Mäntynen T, Mauranen K, Kunnamo I, Juhola M. Is it possible to reduce endoscopy workload using age, alarm symptoms and H. pylori as predictors of peptic ulcer and oesophagogastric cancers? Dig Liver Dis 2005;37:526-32. [PMID: 15975541 DOI: 10.1016/j.dld.2005.01.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
31 Dickman R, Fass R. Functional heartburn. Curr Treat Options Gastroenterol 2005;8:285-91. [PMID: 16009029 DOI: 10.1007/s11938-005-0021-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
32 Walker SJ, Byrne JP, Birbeck N. What’s new in the pathology, pathophysiology and management of benign esophageal disorders? Diseases of the Esophagus 1999;12:219-37. [DOI: 10.1046/j.1442-2050.1999.00056.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Pace F, Pace M. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 2010;4:423-7. [PMID: 20678016 DOI: 10.1586/egh.10.38] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
34 Madan K, Ahuja V, Gupta SD, Bal C, Kapoor A, Sharma MP. Impact of 24-h esophageal pH monitoring on the diagnosis of gastroesophageal reflux disease: defining the gold standard. J Gastroenterol Hepatol. 2005;20:30-37. [PMID: 15610443 DOI: 10.1111/j.1440-1746.2004.03530.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
35 Dhiman RK, Saraswat VA, Naik SR. Ambulatory esophageal pH monitoring: technique, interpretations, and clinical indications. Dig Dis Sci 2002;47:241-50. [PMID: 11855537 DOI: 10.1023/a:1013763616262] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
36 Fass R, Ofman JJ. Gastroesophageal reflux disease--should we adopt a new conceptual framework? Am J Gastroenterol. 2002;97:1901-1909. [PMID: 12190152 DOI: 10.1111/j.1572-0241.2002.05912.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 70] [Article Influence: 1.6] [Reference Citation Analysis]
37 van Pinxteren B, Numans M, Bonis P, Lau J, Numans M. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd002095.pub2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
38 Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-314. [PMID: 11232668 DOI: 10.1111/j.1572-0241.2001.03511.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 149] [Article Influence: 5.1] [Reference Citation Analysis]
39 de Leone A, Tonini M, Dominici P, Grossi E, Pace F; EMERGE Study Group. The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration. Dig Liver Dis 2010;42:785-90. [PMID: 20452300 DOI: 10.1016/j.dld.2010.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
40 Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease: MANAGEMENT STRATEGIES FOR GASTRO-OESOPHAGEAL REFLUX DISEASE. Alimentary Pharmacology & Therapeutics 2002;16:261-73. [DOI: 10.1046/j.1365-2036.2002.01167.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
41 Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998;56:307-335. [PMID: 9777309 DOI: 10.2165/00003495-199856030-00002] [Cited by in Crossref: 164] [Cited by in F6Publishing: 144] [Article Influence: 7.5] [Reference Citation Analysis]
42 Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;CD002095. [PMID: 23728637 DOI: 10.1002/14651858.cd002095.pub5] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
43 Younes Z, Johnson DA. DIAGNOSTIC EVALUATION IN GASTROESOPHAGEAL REFLUX DISEASE. Gastroenterology Clinics of North America 1999;28:809-30. [DOI: 10.1016/s0889-8553(05)70091-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
44 Hölscher AH, Bollschweiler E, Gutschow Ch, Malfertheiner P. [Correct diagnosis for indication in gastroesophageal reflux disease]. Chirurg 2005;76:345-52. [PMID: 15818506 DOI: 10.1007/s00104-004-0955-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Fass R, Achem SR. Noncardiac chest pain: diagnostic evaluation. Dis Esophagus 2012;25:89-101. [PMID: 21777340 DOI: 10.1111/j.1442-2050.2011.01225.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
46 Zentilin P, Savarino V, Mastracci L, Spaggiari P, Dulbecco P, Ceppa P, Savarino E, Parodi A, Mansi C, Fiocca R. Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group. Am J Gastroenterology 2005;100:2299-306. [DOI: 10.1111/j.1572-0241.2005.50209.x] [Cited by in Crossref: 143] [Cited by in F6Publishing: 132] [Article Influence: 8.9] [Reference Citation Analysis]
47 Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007;CD001216. [PMID: 17253456 DOI: 10.1002/14651858] [Cited by in Crossref: 2625] [Cited by in F6Publishing: 769] [Article Influence: 187.5] [Reference Citation Analysis]
48 Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut. 2002;51:885-892. [PMID: 12427796 DOI: 10.1136/gut.51.6.885] [Cited by in Crossref: 161] [Cited by in F6Publishing: 146] [Article Influence: 8.5] [Reference Citation Analysis]
49 Shimoyama Y, Kusano M, Sugimoto S, Kawamura O, Maeda M, Minashi K, Kuribayashi S, Higuchi T, Zai H, Ino K. Diagnosis of gastroesophageal reflux disease using a new questionnaire. J Gastroenterol Hepatol. 2005;20:643-647. [PMID: 15836717 DOI: 10.1111/j.1440-1746.2005.03776.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
50 Madsen LG, Bytzer P. Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design. Aliment Pharmacol Ther. 2004;20:365-372. [PMID: 15274674 DOI: 10.1111/j.1365-2036.2004.02072.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
51 Cohen H, Moraes-Filho JP, Cafferata ML, Tomasso G, Salis G, González O, Valenzuela J, Sharma P, Malfertheiner P, Armstrong D, Lundell L, Corti R, Sakai P, Ceconello I; Latin-American GORD Consensus Group. An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2006;18:349-68. [PMID: 16538106 DOI: 10.1097/00042737-200604000-00008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100:190-200. [PMID: 15654800 DOI: 10.1111/j.1572-0241.2005.41217.x] [Cited by in Crossref: 562] [Cited by in F6Publishing: 444] [Article Influence: 35.1] [Reference Citation Analysis]
53 van Pinxteren B, Numans ME, Lau J, de Wit NJ, Hungin AP, Bonis PA. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med 2003;18:755-63. [PMID: 12950485 DOI: 10.1046/j.1525-1497.2003.20833.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
54 Ofman JJ, Gralnek IM, Udani J, Fennerty M, Fass R. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. The American Journal of Medicine 1999;107:219-27. [DOI: 10.1016/s0002-9343(99)00219-3] [Cited by in Crossref: 66] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
55 Baldi F, Cappiello R, Cavoli C, Ghersi S, Torresan F, Roda E. Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: A comparison between two different daily doses of lansoprazole. World J Gastroenterol 2006; 12(1): 82-88 [PMID: 16440422 DOI: 10.3748/wjg.v12.i1.82] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
56 Heading RC. Review article: diagnosis and clinical investigation of gastro-oesophageal reflux disease: a European view. Aliment Pharmacol Ther. 2004;20 Suppl 8:9-13. [PMID: 15575865 DOI: 10.1111/j.1365-2036.2004.02221.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
57 Shapiro M, Green C, Bautista JM, Peru RL, Malagon IB, Corvo M, Risner-Adler S, Beeler JN, Tuchinsky I, Fass R. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006;101:1084-91. [PMID: 16573776 DOI: 10.1111/j.1572-0241.2006.00525.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
58 Zhang M, Pandolfino JE, Zhou X, Tan N, Li Y, Chen M, Xiao Y. Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis. Therap Adv Gastroenterol 2019;12:1756284819890537. [PMID: 31803253 DOI: 10.1177/1756284819890537] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
59 Frazzoni M, De Micheli E, Zentilin P, Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther. 2004;20:81-88. [PMID: 15225174 DOI: 10.1111/j.1365-2036.2004.01998.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
60 Aanen MC, Weusten BL, Numans ME, de Wit NJ, Samsom M, Smout AJ. Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association. J Clin Gastroenterol 2008;42:441-7. [PMID: 18344896 DOI: 10.1097/MCG.0b013e318074dd62] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
61 Tolman KG, Chandramouli J, Fang JC. Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opinion on Pharmacotherapy 2005;1:1171-94. [DOI: 10.1517/14656566.1.6.1171] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
62 Fofaria RK, Morris DL. Hiatus hernia and gastro-oesophageal reflux disease. Medicine 2015;43:192-6. [DOI: 10.1016/j.mpmed.2015.01.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Tseng P, Lee Y, Chiu H, Wang H, Lin J, Wu M. A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes. Journal of Clinical Gastroenterology 2009;43:920-5. [DOI: 10.1097/mcg.0b013e3181960628] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
64 Bruley des Varannes S. The proton-pump inhibitor test: pros and cons. Eur J Gastroenterol Hepatol. 2004;16:847-852. [PMID: 15316406 DOI: 10.1097/00042737-200409000-00005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
65 Tipnis NA, Rudolph CD. Treatment options in pediatric GERD. Curr Treat Options Gastro 2007;10:391-400. [DOI: 10.1007/s11938-007-0039-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Vieth M. Contribution of histology to the diagnosis of reflux disease. Best Practice & Research Clinical Gastroenterology 2008;22:625-38. [DOI: 10.1016/j.bpg.2008.02.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 DeVault KR. Overview of medical therapy for gastroesophageal reflux disease. Gastroenterol Clin North Am. 1999;28:831-845. [PMID: 10695004 DOI: 10.1016/s0889-8553(05)70092-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
68 Juul-hansen P, Rydning A. On-demand PPI Requirements in Patients With Endoscopy-Negative GERD: . Journal of Clinical Gastroenterology 2004;38:746-9. [DOI: 10.1097/01.mcg.0000139033.30945.7f] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
69 Wong WM, Wong BC. Definition and diagnosis of gastroesophageal reflux disease. J Gastroenterol Hepatol 2004;19 Suppl 3:S26-32. [PMID: 15324379 DOI: 10.1111/j.1440-1746.2004.03588.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
70 Gerson LB, Hatton BN, Ryono R, Jones W, Pulliam G, Sampliner RE, Triadafilopoulos G, Fass R. Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000;14:397-406. [PMID: 10759618 DOI: 10.1046/j.1365-2036.2000.00726.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
71 Iwakiri K, Kinoshita Y, Habu Y, Oshima T, Manabe N, Fujiwara Y, Nagahara A, Kawamura O, Iwakiri R, Ozawa S, Ashida K, Ohara S, Kashiwagi H, Adachi K, Higuchi K, Miwa H, Fujimoto K, Kusano M, Hoshihara Y, Kawano T, Haruma K, Hongo M, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol. 2016;51:751-767. [PMID: 27325300 DOI: 10.1007/s00535-016-1227-8] [Cited by in Crossref: 142] [Cited by in F6Publishing: 115] [Article Influence: 28.4] [Reference Citation Analysis]
72 Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI. Am J Gastroenterol 2009;104:S27-32. [DOI: 10.1038/ajg.2009.49] [Cited by in Crossref: 88] [Cited by in F6Publishing: 92] [Article Influence: 7.3] [Reference Citation Analysis]
73 Peura DA, Gudmundson J, Siepman N, Pilmer BL, Freston J. Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 2007;52:983-7. [PMID: 17342402 DOI: 10.1007/s10620-006-9156-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
74 Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs. 1998;56:447-486. [PMID: 9777317 DOI: 10.2165/00003495-199856030-00012] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 3.2] [Reference Citation Analysis]
75 Lee Y, Lin J, Wang H, Chiu H, Wu M. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J Gastroenterol Hepatol 2007;22:1286-92. [DOI: 10.1111/j.1440-1746.2007.04942.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
76 Sharma P, Wani S, Bansal A, Hall S, Puli S, Mathur S, Rastogi A. A feasibility trial of narrow band imaging endoscopy in patients with gastroesophageal reflux disease. Gastroenterology. 2007;133:454-464; quiz 674. [PMID: 17681166 DOI: 10.1053/j.gastro.2007.06.006] [Cited by in Crossref: 91] [Cited by in F6Publishing: 81] [Article Influence: 6.5] [Reference Citation Analysis]
77 Maeda T, Nagata K, Satoh Y, Yamazaki T, Takano D. High prevalence of gastroesophageal reflux disease in Parkinson's disease: a questionnaire-based study. Parkinsons Dis 2013;2013:742128. [PMID: 23476890 DOI: 10.1155/2013/742128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
78 Rudolph CD, Mazur LJ, Liptak GS, Baker RD, Boyle JT, Colletti RB, Gerson WT, Werlin SL. Guidelines for Evaluation and Treatment of Gastroesophageal Reflux in Infants and Children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. Journal of Pediatric Gastroenterology and Nutrition 2001;32:S1-S31. [DOI: 10.1097/00005176-200100002-00001] [Cited by in Crossref: 442] [Cited by in F6Publishing: 342] [Article Influence: 22.1] [Reference Citation Analysis]
79 Quigley EM. Non-erosive reflux disease, functional heartburn and gastroesophageal reflux disease; insights into pathophysiology and clinical presentation. Chin Dig Dis 2006;7:186-90. [DOI: 10.1111/j.1443-9573.2006.00266.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
80 DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol. 1999;94:1434-1442. [PMID: 10364004 DOI: 10.1111/j.1572-0241.1999.1123_a.x] [Cited by in Crossref: 286] [Cited by in F6Publishing: 236] [Article Influence: 13.0] [Reference Citation Analysis]
81 An evidence-based appraisal of reflux disease management--the Genval Workshop Report. Gut. 1999;44 Suppl 2:S1-16. [PMID: 10741335 DOI: 10.1136/gut.44.2008.s1] [Cited by in Crossref: 545] [Cited by in F6Publishing: 113] [Article Influence: 26.0] [Reference Citation Analysis]
82 Bytzer P. Assessment of reflux symptom severity: methodological options and their attributes. Gut. 2004;53 Suppl 4:iv28-iv34. [PMID: 15082611 DOI: 10.1136/gut.2003.034298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
83 Lee SH, Jang BI, Jeon SW, Kwon JG, Kim EY, Cho KB, Park CG, Yang CH; Daegu-Gyeongbuk Gastrointestinal Study Group. A multicenter, randomized, comparative study to determine the appropriate dose of lansoprazole for use in the diagnostic test for gastroesophageal reflux disease. Gut Liver 2011;5:302-7. [PMID: 21927658 DOI: 10.5009/gnl.2011.5.3.302] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
84 Pace F, Riegler G, Leone A, Dominici P, Grossi E, Group TES. Gastroesophageal reflux disease management according to contemporary international guidelines: A translational study. World J Gastroenterol 2011; 17(9): 1160-1166 [PMID: 21448420 DOI: 10.3748/wjg.v17.i9.1160] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
85 van Pinxteren B, Sigterman KE, Bonis P, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2010;CD002095. [PMID: 21069670 DOI: 10.1002/14651858.cd002095.pub4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
86 Metz DC. Therapy for gastroesophageal reflux disease: more is not necessarily better. Am J Gastroenterology 2003;98:1913-5. [DOI: 10.1111/j.1572-0241.2003.07668.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
87 Armstrong D. Symptom Assessment: Methods and Content. Journal of Clinical Gastroenterology 2007;41:S184-92. [DOI: 10.1097/mcg.0b013e318042d636] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
88 Kroes RM, Numans ME, Jones RH, de Wit NJ, Verheij TJ. Original Paper: Gastro-oesophageal reflux disease in primary care Comparison and evaluation of existing national guidelines and development of uniform European guidelines. European Journal of General Practice 2009;5:88-97. [DOI: 10.3109/13814789909094270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
89 Kawaguchi S, Takeuchi T, Inoue Y, Takahashi Y, Ozaki H, Ota K, Harada S, Edogawa S, Kojima Y, Yamashita H, Fukuchi T, Ashida K, Higuchi K. Exploratory Research on Latent Esophageal Motility Disorders in Dysphagia Patients. Digestion 2017;95:269-74. [DOI: 10.1159/000470901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]